Study summary · research use only
Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study used human non-stem-cell acute myelogenous leukemia cell lines (U937, OCI-AML3, and HL60) to examine membrane HDM-2 expression and the effects of the anticancer peptide PNC-27, which binds membrane HDM-2 to form cytotoxic transmembrane pores. Cell surface HDM-2 was measured by flow cytometry, viability by MTT assay, and cytotoxicity by lactate dehydrogenase release and induction of the apoptotic markers annexin V and caspase-3. The abstract reports that HDM-2 was expressed at high levels in the membranes of all three lines and that PNC-27 bound membrane HDM-2 and induced cell necrosis and LDH release within 4 h. The authors describe targeting membrane HDM-2 as a potential strategy for leukemia.
Abstract
Anticancer peptide PNC-27 binds to HDM-2 protein on cancer cell membranes inducing the formation of cytotoxic transmembrane pores. Herein, we investigated HDM-2 membrane expression and the effect of PNC-27 treatment on human non-stem cell acute myelogenous leukemia cell lines: U937, acute monocytic leukemia; OCI-AML3, acute myelomonocytic leukemia and HL60, acute promyelocytic leukemia. We measured cell surface membrane expression of HDM-2 using flow cytometry. Cell viability was assessed using MTT assay while direct cytotoxicity was measured by lactate dehydrogenase (LDH) release and induction of apoptotic markers annexin V and caspase-3. HDM-2 is expressed at high levels in membranes of U937, OCI-AML3 and HL-60 cells. PNC-27 can bind to membrane HDM-2 to induce cell necrosis and LDH release within 4 h. Targeting membrane HDM-2 can be a potential strategy to treat leukemia. PNC-27 targeting membrane HDM-2 demonstrated significant anti-leukemia activity in a variety of leukemic cell lines.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.